IR
66
3
MCHP
41
4
BMY
60
2
LYB
39
2
CHRW
56
-3
GE
67
2
PBI
69
4
KMB
39
2
DTE
56
2
TROW
56
5
DD
63
3
CFG
70
6
DOW
44
10
HOG
35
2
MLM
57
6
PYPL
54
2
EBAY
47
4
BA
54
5
URI
65
5
ISRG
74
-2
IR
66
3
MCHP
41
4
BMY
60
2
LYB
39
2
CHRW
56
-3
GE
67
2
PBI
69
4
KMB
39
2
DTE
56
2
TROW
56
5
DD
63
3
CFG
70
6
DOW
44
10
HOG
35
2
MLM
57
6
PYPL
54
2
EBAY
47
4
BA
54
5
URI
65
5
ISRG
74
-2
Financhill
Back

Black Diamond Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
40

BDTX
Black Diamond Therapeutics

Last Price:
2.55
Seasonality Move:
28.2%

7 Day Trial

ALL ACCESS PASS

$ 7

Trade on Tuesday. Profit on Friday. Rinse & Repeat

Get the full details now.

Black Diamond Therapeutics Price Quote

$2.55
+0.01 (+4.94%)
(Updated: November 23, 2024 at 5:26 AM ET)

Black Diamond Therapeutics Key Stats

Sell
40
Black Diamond Therapeutics (BDTX) is a Sell
Day range:
$2.40 - $2.62
52-week range:
$2.16 - $7.66
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
1.48%
Volume:
598.8K
Avg. volume:
599.9K
1-year change:
8.55%
Market cap:
$143.7M
Revenue:
$0
EPS:
$-1.33

How Much Does Black Diamond Therapeutics Make?

Data Unavailable

Is Black Diamond Therapeutics Growing As A Company?

Data Unavailable

Black Diamond Therapeutics Stock Price Performance

What Is Black Diamond Therapeutics 52-Week High & Low?

Black Diamond Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Black Diamond Therapeutics?

Is Black Diamond Therapeutics Cash Flow Positive?

  • What Is BDTX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$61.2M
  • What Is Black Diamond Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $25.2M
  • What Is Black Diamond Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $1.4M

Black Diamond Therapeutics Return On Invested Capital

Data Unavailable

Black Diamond Therapeutics Earnings Date & Stock Price

Black Diamond Therapeutics Competitors

Black Diamond Therapeutics Dividend Yield

Black Diamond Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 21.5%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 14.50
Upside from Last Price: 470.87%

Major Shareholders

  • How many BDTX shares are owned by institutional investors?
    95.4M BDTX shares are owned by institutional investors
  • How many BDTX shares are owned by insiders?
    1.2M BDTX shares are owned by insiders